Payment overview · 2025
General Payments
$797.71
42 reported records · 11 companies
Healthcare provider profile · identity verified
Claudius Stuart Dawson, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SUMMERVILLE, SC · NPI 1780675306
Verified facts
What the public records show
CMS Open Payments records show Claudius Stuart Dawson, M.D. received $797.71 in general payments during 2025 across 42 reported records.
ABBVIE INC. accounted for 22.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Rybelsus, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 229 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $182.52 | 22.9% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $122.61 | 15.4% | 7 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $98.19 | 12.3% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $82.76 | 10.4% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $80.76 | 10.1% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $64.09 | 8.0% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $47.72 | 6.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $37.87 | 4.8% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $33.83 | 4.2% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $28.26 | 3.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.10 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $797.71 | 42 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $98.19 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $90.91 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $89.69 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $89.69 | 5 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $82.76 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $80.76 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $74.72 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $69.79 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $47.72 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $33.83 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $32.92 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $28.26 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $28.09 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $28.09 | 2 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $22.19 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $21.85 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $21.82 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.10 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $19.10 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $18.23 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $17.77 | 1 | 2025 |
Source payment records
|
|||||
| Repatha Normalized: repatha |
Biological | Amgen Inc. | $16.02 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 55 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 229 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 32 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
32 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
55 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
43 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
229 | 47 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
109 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 628 | 183 |
| Amlodipine Besylate | Amlodipine Besylate | 572 | 170 |
| Atorvastatin Calcium | Atorvastatin Calcium | 570 | 174 |
| Levothyroxine Sodium | Levothyroxine Sodium | 506 | 142 |
| Losartan Potassium | Losartan Potassium | 458 | 133 |
| Omeprazole | Omeprazole | 414 | 122 |
| Gabapentin | Gabapentin | 386 | 101 |
| Lisinopril | Lisinopril | 287 | 81 |
| Trazodone Hcl | Trazodone Hcl | 285 | 68 |
| Metformin Hcl | Metformin Hcl | 273 | 92 |
| Metoprolol Succinate | Metoprolol Succinate | 252 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 238 | 77 |
| Ozempic | Semaglutide | 229 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 224 | 70 |
| Zolpidem Tartrate | Zolpidem Tartrate | 219 | 41 |
| Azithromycin | Azithromycin | 214 | 144 |
| Alprazolam | Alprazolam | 176 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 174 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 171 | 55 |
| Lorazepam | Lorazepam | 167 | 38 |
| Famotidine | Famotidine | 160 | 46 |
| Farxiga | Dapagliflozin Propanediol | 156 | 28 |
| Prednisone | Prednisone | 154 | 99 |
| Duloxetine Hcl | Duloxetine Hcl | 152 | 37 |
| Citalopram Hbr | Citalopram Hydrobromide | 144 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 143 | 46 |
| Tizanidine Hcl | Tizanidine Hcl | 143 | 47 |
| Valsartan | Valsartan | 139 | 40 |
| Montelukast Sodium | Montelukast Sodium | 136 | 45 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 134 | 25 |
| Simvastatin | Simvastatin | 134 | 43 |
| Furosemide | Furosemide | 132 | 53 |
| Ezetimibe | Ezetimibe | 129 | 46 |
| Fluticasone Propionate | Fluticasone Propionate | 129 | 55 |
| Carvedilol | Carvedilol | 128 | 40 |
| Meloxicam | Meloxicam | 126 | 38 |
| Allopurinol | Allopurinol | 125 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 124 | 37 |
| Potassium Chloride | Potassium Chloride | 122 | 37 |
| Clonazepam | Clonazepam | 118 | 17 |
| Buspirone Hcl | Buspirone Hcl | 117 | 28 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 110 | 90 |
| Eliquis | Apixaban | 109 | 32 |
| Sertraline Hcl | Sertraline Hcl | 104 | 31 |
| Metformin Hcl Er | Metformin Hcl | 99 | 29 |
| Pioglitazone Hcl | Pioglitazone Hcl | 98 | 26 |
| Oxycodone Hcl | Oxycodone Hcl | 95 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 95 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 93 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 80 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 80 | 24 |
| Cephalexin | Cephalexin | 79 | 62 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 79 | 20 |
| Glipizide Er | Glipizide | 78 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 76 | 49 |
| Bupropion Xl | Bupropion Hcl | 74 | 21 |
| Diazepam | Diazepam | 73 | 14 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 71 | suppressed |
| Fluconazole | Fluconazole | 71 | 48 |
| Fluoxetine Hcl | Fluoxetine Hcl | 70 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 69 | 19 |
| Atenolol | Atenolol | 68 | 18 |
| Methylprednisolone | Methylprednisolone | 68 | 56 |
| Pregabalin | Pregabalin | 65 | 13 |
| Aripiprazole | Aripiprazole | 63 | 16 |
| Mirtazapine | Mirtazapine | 61 | 18 |
| Celecoxib | Celecoxib | 60 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 58 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 57 | 15 |
| Donepezil Hcl | Donepezil Hcl | 55 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 55 | 15 |
| Jardiance | Empagliflozin | 55 | 21 |
| Colchicine | Colchicine | 54 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 54 | suppressed |
| Januvia | Sitagliptin Phosphate | 53 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 53 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | 13 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 49 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 49 | 39 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 34 |
| Clonidine Hcl | Clonidine Hcl | 48 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 48 | 18 |
| Alendronate Sodium | Alendronate Sodium | 47 | 15 |
| Spironolactone | Spironolactone | 46 | 19 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 45 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 45 | 13 |
| Trulicity | Dulaglutide | 43 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 43 | 12 |
| Mupirocin | Mupirocin | 42 | 32 |
| Valacyclovir | Valacyclovir Hcl | 41 | 18 |
| Meclizine Hcl | Meclizine Hcl | 39 | 21 |
| Nystatin | Nystatin | 39 | 17 |
| Temazepam | Temazepam | 37 | suppressed |
| Ibuprofen | Ibuprofen | 36 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 35 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 35 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 34 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 34 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 34 | 13 |
| Carisoprodol | Carisoprodol | 33 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 33 | suppressed |
| Synthroid | Levothyroxine Sodium | 32 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 32 | suppressed |
| Topiramate | Topiramate | 32 | 14 |
| Finasteride | Finasteride | 31 | suppressed |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Hydrocortisone | Hydrocortisone | 30 | suppressed |
| Eszopiclone | Eszopiclone | 29 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 28 | suppressed |
| Ramipril | Ramipril | 28 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 28 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 27 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 27 | suppressed |
| Linzess | Linaclotide | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Primidone | Primidone | 25 | suppressed |
| Telmisartan | Telmisartan | 25 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 24 | 15 |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 24 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 19 |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | 11 |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 15 |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Phenobarbital | Phenobarbital | 19 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Risperidone | Risperidone | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | 12 |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 12 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 12 | 11 |
| Haloperidol | Haloperidol | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | 11 |
| Lunesta | Eszopiclone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $797.71 · 42 records | ABBVIE INC. | ACCRUFER, CAPLYTA, Dexcom G6 Transmitter, ENTRESTO, GEMTESA, JARDIANCE, KISUNLA, KRYSTEXXA, Korlym, LEQVIO, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, Repatha, Rybelsus, SYNTHROID, UBRELVY, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error